Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/245524
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorKoller, Doraes_ES
dc.date.accessioned2021-07-08T13:12:03Z-
dc.date.available2021-07-08T13:12:03Z-
dc.date.issued2021-06-30-
dc.identifier.citationKoller, Dora (2021) "Dataset related to Doctoral Thesis: Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapine [Dataset]", http://dx.doi.org/10.20350/digitalCSIC/13933es_ES
dc.identifier.urihttp://hdl.handle.net/10261/245524-
dc.descriptionFile 1. Adverse events_TREATMENT The xls file shows relevant information about the treatment with aripiprazole and olanzapine, as well as about their possible adverse effects and the frequency with which they occur. File 2. Genotype Matrix. The xls file show the detected genetic polymorphism associated with the effects of aripiprazole and olanzapinees_ES
dc.description.abstractAripiprazole altered pupil contraction. Olanzapine caused significant prolactin and weight elevation. Glucose levels in glucose tolerance test were higher after olanzapine treatment. Moreover, olanzapine had more cardiovascular effects than aripiprazole. However, aripiprazole was associated to more psychiatric and nervous system adverse drug reactions. Many polymorphisms may influence pupillometric and metabolic parameters along with cardiovascular changes and adverse events. Moreover, several polymorphisms had an effect on aripiprazole, dehydro-aripiprazole and olanzapine pharmacokinetics. It seems that aripiprazole provokes less severe metabolic and cardiovascular changes, however, more adverse drug reactions were registered to it compared to olanzapine.es_ES
dc.description.sponsorshipEuropean Comission ITN Treatment H2020-MSCA-ITN-721236es_ES
dc.formatapplication/vnd.ms-exceles_ES
dc.language.isoenges_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/721236es_ES
dc.relation.isreferencedbyKoller, Dora. (2020). Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapine. http://hdl.handle.net/10486/693933. http://hdl.handle.net/10261/245523es_ES
dc.rightsopenAccessen_EN
dc.subjectAntipsychoticses_ES
dc.subjectPharmageneticses_ES
dc.subjectSide effectses_ES
dc.subjectAntipsychoticses_ES
dc.subjectAdverse Reactionses_ES
dc.titleDataset related to Doctoral Thesis: Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapinees_ES
dc.typedatasetes_ES
dc.identifier.doi10.20350/digitalCSIC/13933-
dc.description.peerreviewedPeer reviewedes_ES
dc.rights.licensehttps://creativecommons.org/licenses/by-sa/4.0/es_ES
dc.contributor.funderEuropean Commissiones_ES
dc.relation.csicNoes_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.type.coarhttp://purl.org/coar/resource_type/c_ddb1es_ES
item.cerifentitytypeProducts-
item.openairecristypehttp://purl.org/coar/resource_type/c_ddb1-
item.grantfulltextopen-
item.openairetypedataset-
item.fulltextWith Fulltext-
item.languageiso639-1en-
Aparece en las colecciones: (IIBM) Conjuntos de datos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Adverse events_TREATMENT-HV_v.22.xlsx51,58 kBMicrosoft Excel XMLVisualizar/Abrir
Genotype Matrix_TREATMENT_clean.xlsx64,02 kBMicrosoft Excel XMLVisualizar/Abrir
Show simple item record

CORE Recommender
fair
fair eva

Page view(s)

124
checked on 01-may-2024

Download(s)

12
checked on 01-may-2024

Google ScholarTM

Check

Altmetric

Altmetric


Este item está licenciado bajo una Licencia Creative Commons Creative Commons